title: Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.
abstract: Seventy-three patients infected with human immunodeficiency virus type 1 (HIV-1) were enrolled in a prospective observational study to investigate the efficacy and tolerance of substituting a nonnucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients whose plasma viral load (pVL) was controlled by a PI regimen. After a median follow-up of 52 weeks, 63 patients (86.3%) had undetectable pVLs. The incidence of virological breakthrough at 12 months of follow-up was 6.5% (95% confidence interval [CI], 1-20) among patients who had been antiretroviral naive before receiving HAART and 19.2% (95% CI, 6-34) among patients who had been treated with antiretroviral drugs before receiving the PI regimen (P=.10).
authors.affiliation: Infectious Diseases Unit, University Hospital Nantes, Nantes, France. francois.raffi@wanadoo.fr
authors.forename: F
authors.initials: F
authors.lastname: Raffi
authors.forename: B
authors.initials: B
authors.lastname: Bonnet
authors.forename: V
authors.initials: V
authors.lastname: Ferré
authors.forename: J L
authors.initials: JL
authors.lastname: Esnault
authors.forename: P
authors.initials: P
authors.lastname: Perré
authors.forename: V
authors.initials: V
authors.lastname: Reliquet
authors.forename: S
authors.initials: S
authors.lastname: Leautez
authors.forename: C
authors.initials: C
authors.lastname: Bouillant
authors.forename: O
authors.initials: O
authors.lastname: Vergnoux
authors.forename: P
authors.initials: P
authors.lastname: Weinbreck
mesh_terms: D018791:CD4 Lymphocyte Count; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011480:Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors